Bio-Rad's flat third quarter hides split between diagnostics and life science

Bio-Rad Laboratories ended the third quarter of 2026 with revenue of $656.4 million, up half a percent on the year, according to results published on 4 November. The headline number conceals two businesses heading in different directions.

Clinical Diagnostics, the larger of the two segments in the company's reporting, expanded 2.7%. Life Science contracted 2.8%. The company's announcement, as available to CompePharma, did not break the movements down by product line or region, so the reasons behind each trend are not covered here.

Reported (GAAP) net income came in at $458.6 million. Bio-Rad said the figure was driven largely by a fair-value change on its investment in Sartorius AG. That is a valuation effect on a shareholding, not income generated by selling products, so the profit line says little about how the core operations performed.

Management kept its full-year 2026 guidance as it stood. It still projects currency-neutral revenue anywhere between a 3.0% decline and 0.5% growth, with a non-GAAP operating margin of roughly 10% to 12%. The range is wide, and the unchanged outlook means the company has not signalled any shift in its expectations after the quarter.